#Lucica #Glycated Albumin #Precision Diabetes

Precision Diabetes and Nagase Diagnostics: A New Era in Diabetes Management

In a significant move for diabetes care, Precision Diabetes, Inc. and Nagase Diagnostics Co., Ltd. have forged an exclusive partnership for the commercialization of the Lucica® Glycated Albumin-L assay in the United States. This partnership marks the introduction of the only FDA-cleared assay specifically designed to measure glycated albumin, a crucial biomarker for assessing glycemic control.

This innovative testing method is crucial for healthcare professionals aiming to provide personalized diabetes management. Unlike the traditional HbA1c test, which gives an average blood sugar level over the prior two to three months, the Lucica® Glycated Albumin-L assay can provide insights from just the past two to three weeks. This shorter time frame enables clinicians to evaluate and adjust treatment plans more swiftly, leading to better outcomes for patients.

The collaboration capitalizes on Nagase Diagnostics' expertise in developing diagnostic reagents and Precision Diabetes' leadership in diabetes biomarkers and laboratory commercialization. Together, they aim to enhance the accessibility of this advanced diagnostic tool across the U.S. healthcare system.

With diabetes management evolving toward more individualized care approaches, the introduction of this assay provides an additional layer of clinical insight. There is growing evidence that links the Lucica® Glycated Albumin-L assay outcomes with Continuous Glucose Monitoring (CGM) metrics, which also assess glucose levels over time. This integration offers healthcare providers a comprehensive toolkit to manage diabetes more effectively.

Moreover, the assay holds particular significance for patients with chronic kidney disease, as HbA1c interpretations can be inaccurate due to altered red blood cell survival in these individuals. Additionally, patients involved in hemodialysis often see limited benefits from HbA1c assessments. Because the Lucica assay operates independently of red blood cell lifespan, it may provide clearer insights for this challenging demographic.

Not only does the Lucica® Glycated Albumin-L assay optimize glycemic control assessments in chronic kidney disease, but it also serves vital roles during pregnancy—including gestational diabetes—and for patients experiencing conditions that affect red blood cell turnover, such as hemoglobinopathies and other forms of anemia.

The innovative nature of this assay does not stop at its operational specifications. By exclusively measuring glycated albumin—a more targeted indicator of glycemic fluctuations—this assay is described to offer greater analytical specificity compared to older, less precise methods like fructosamine tests.

Makise Hironao, Representative Director of Nagase Diagnostics, expressed excitement about the new partnership, stating that